Key Drivers
- Positive EBITDA
- High leverage
- Rich multiples
AIAI Summary
RadNet's thesis now hinges on converting DeepHealth from a productivity tool into scalable, high-margin external software revenue that could justify current rich multiples, but successful monetization timing and integration are the binary catalysts. Monitor quarterly digital ARR/margins, evidence of recurring SaaS revenue, and net leverage trends—missed monetization or impairments would likely trigger sharp multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive EBITDA
- •High leverage
- •Rich multiples
RDNT generates solid EBITDA and free cash flow with ample liquidity, but persistent GAAP losses, heavy D&A, and high leverage combined with rich valuation create material solvency and return risks.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Failed support
- •Measured floor
RDNT is in a clear short-term downtrend over the last month, sliding from the low-$70s to the low-$60s with failed support at $66–70 and a measured intraperiod floor near $59.78, leaving momentum biased lower until a sustained reclaim of the mid-$60s/70s occurs.
Rapid decline from low-$70s to low-$60s over the last month, breaking below the 66–70 area
Sentiment & News
Key News Insights:
- •Record revenue
- •Gleamer acquisition
- •DeepHealth CE-mark
RadNet reported record Q4 and full-year revenue and adjusted EBITDA with better-than-expected EPS, driven by strong outpatient imaging demand, acquisitions (Gleamer) and AI integration (DeepHealth), prompting upbeat guidance and increased investor engagement.
The results and strategic AI/acquisition moves should support upward share momentum and position RadNet for continued organic and M&A-driven growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings